Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR2 | Q9NS75 | 7/20 | 0.56 |
| ▸ | CYSLTR1 | Q9Y271 | 7/20 | 0.56 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.56 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.50 |
| ▸ | CDC25A | P30304 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.45 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.43 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
| ▸ | MMP9 | P14780 | 1/20 | 0.43 |
| ▸ | MMP12 | P39900 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27261843 | 1.00 | CYSLTR2 (0.56) | CYSLTR2CYSLTR1PTGS2EPHX2CDC25A | |
| SCHEMBL202369 | 0.79 | PTGS2 (0.54) | CYSLTR2CYSLTR1PTGS2EPHX2 | |
| SCHEMBL199656 | 0.79 | PTGS2 (0.54) | CYSLTR2CYSLTR1PTGS2EPHX2 | |
| SCHEMBL10888245 | 0.79 | PTGS2 (0.54) | CYSLTR2CYSLTR1PTGS2EPHX2 | |
| SCHEMBL11768735 | 0.78 | PTGS2 (0.58) | CYSLTR2CYSLTR1PTGS2EPHX2 | |
| SCHEMBL12080328 | 0.78 | PTGS2 (0.58) | CYSLTR2CYSLTR1PTGS2EPHX2 | |
| SCHEMBL11769795 | 0.78 | PTGS2 (0.58) | CYSLTR2CYSLTR1PTGS2EPHX2 | |
| SCHEMBL11301411 | 0.78 | PTGS2 (0.58) | CYSLTR2CYSLTR1PTGS2EPHX2 | |
| SCHEMBL231917 | 0.78 | PTGS2 (0.58) | CYSLTR2CYSLTR1PTGS2EPHX2 | |
| SCHEMBL9139729 | 0.78 | PTGS2 (0.58) | CYSLTR2CYSLTR1PTGS2EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060247458-A1 | Process for the production of optically active compounds having substituents at the 2-position | KANEKA CORPORATION (JP) | 2006-11-02 | — | — | US | disclosed |
| EP-1600438-A1 | PROCESSES FOR THE PRODUCTION OF OPTICALLY ACTIVE COMPOUNDS HAVING SUBSTITUENTS AT THE 2-POSITION | KANEKA CORPORATION (JP) | 2005-11-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247458-A1 | Process for the production of optically active compounds having substituents at the 2-position | TST, TMT1A, OSGEP | CYSLTR2 395/4885CYSLTR1 750/4885PTGS2 986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.